Effect of L-dopa in young patients with hypertension

I. Saito, H. Kawabe, C. Hasegawa, Y. Iwaida, H. Yamakawa, T. Saruta, E. Takeshita, S. Nagano, T. Sekihara

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The effects of L-dopa on blood pressure, heart rate, plasma renin activity, norepinephrine, epinephrine and prolactin were studied in a randomized single-blind trial in 36 patients with essential hypertension. In response to L-dopa, 250 mg administered orally, the blood pressure decreased significantly as compared with the results of placebo treatment. The heart rate and plasma norepinephrine and epinephrine were unchanged. The plasma renin activity and prolactin decreased as a result of L-dopa administration. The administration of a peripheral DA2 dopamine receptor blocker, domperidone (20 mg, orally) prevented the L-dopa-induced reduction in plasma prolactin but failed to block the fall in blood pressure and plasma renin activity. These results suggest that the blood pressure-lowering effect of L-dopa may be mediated through multiple sites involving D1 dopamine receptors, the central nervous system, and the renin-angiotensin system.

Original languageEnglish
Pages (from-to)691-695
Number of pages5
JournalAngiology
Volume42
Issue number9
Publication statusPublished - 1991

Fingerprint

Levodopa
Hypertension
Renin
Prolactin
Blood Pressure
Epinephrine
Norepinephrine
Heart Rate
Domperidone
Dopamine D1 Receptors
Dopamine Antagonists
Dopamine Receptors
Renin-Angiotensin System
Central Nervous System
Placebos

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Saito, I., Kawabe, H., Hasegawa, C., Iwaida, Y., Yamakawa, H., Saruta, T., ... Sekihara, T. (1991). Effect of L-dopa in young patients with hypertension. Angiology, 42(9), 691-695.

Effect of L-dopa in young patients with hypertension. / Saito, I.; Kawabe, H.; Hasegawa, C.; Iwaida, Y.; Yamakawa, H.; Saruta, T.; Takeshita, E.; Nagano, S.; Sekihara, T.

In: Angiology, Vol. 42, No. 9, 1991, p. 691-695.

Research output: Contribution to journalArticle

Saito, I, Kawabe, H, Hasegawa, C, Iwaida, Y, Yamakawa, H, Saruta, T, Takeshita, E, Nagano, S & Sekihara, T 1991, 'Effect of L-dopa in young patients with hypertension', Angiology, vol. 42, no. 9, pp. 691-695.
Saito I, Kawabe H, Hasegawa C, Iwaida Y, Yamakawa H, Saruta T et al. Effect of L-dopa in young patients with hypertension. Angiology. 1991;42(9):691-695.
Saito, I. ; Kawabe, H. ; Hasegawa, C. ; Iwaida, Y. ; Yamakawa, H. ; Saruta, T. ; Takeshita, E. ; Nagano, S. ; Sekihara, T. / Effect of L-dopa in young patients with hypertension. In: Angiology. 1991 ; Vol. 42, No. 9. pp. 691-695.
@article{9c533773b0174834983919c4c62a95fb,
title = "Effect of L-dopa in young patients with hypertension",
abstract = "The effects of L-dopa on blood pressure, heart rate, plasma renin activity, norepinephrine, epinephrine and prolactin were studied in a randomized single-blind trial in 36 patients with essential hypertension. In response to L-dopa, 250 mg administered orally, the blood pressure decreased significantly as compared with the results of placebo treatment. The heart rate and plasma norepinephrine and epinephrine were unchanged. The plasma renin activity and prolactin decreased as a result of L-dopa administration. The administration of a peripheral DA2 dopamine receptor blocker, domperidone (20 mg, orally) prevented the L-dopa-induced reduction in plasma prolactin but failed to block the fall in blood pressure and plasma renin activity. These results suggest that the blood pressure-lowering effect of L-dopa may be mediated through multiple sites involving D1 dopamine receptors, the central nervous system, and the renin-angiotensin system.",
author = "I. Saito and H. Kawabe and C. Hasegawa and Y. Iwaida and H. Yamakawa and T. Saruta and E. Takeshita and S. Nagano and T. Sekihara",
year = "1991",
language = "English",
volume = "42",
pages = "691--695",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Effect of L-dopa in young patients with hypertension

AU - Saito, I.

AU - Kawabe, H.

AU - Hasegawa, C.

AU - Iwaida, Y.

AU - Yamakawa, H.

AU - Saruta, T.

AU - Takeshita, E.

AU - Nagano, S.

AU - Sekihara, T.

PY - 1991

Y1 - 1991

N2 - The effects of L-dopa on blood pressure, heart rate, plasma renin activity, norepinephrine, epinephrine and prolactin were studied in a randomized single-blind trial in 36 patients with essential hypertension. In response to L-dopa, 250 mg administered orally, the blood pressure decreased significantly as compared with the results of placebo treatment. The heart rate and plasma norepinephrine and epinephrine were unchanged. The plasma renin activity and prolactin decreased as a result of L-dopa administration. The administration of a peripheral DA2 dopamine receptor blocker, domperidone (20 mg, orally) prevented the L-dopa-induced reduction in plasma prolactin but failed to block the fall in blood pressure and plasma renin activity. These results suggest that the blood pressure-lowering effect of L-dopa may be mediated through multiple sites involving D1 dopamine receptors, the central nervous system, and the renin-angiotensin system.

AB - The effects of L-dopa on blood pressure, heart rate, plasma renin activity, norepinephrine, epinephrine and prolactin were studied in a randomized single-blind trial in 36 patients with essential hypertension. In response to L-dopa, 250 mg administered orally, the blood pressure decreased significantly as compared with the results of placebo treatment. The heart rate and plasma norepinephrine and epinephrine were unchanged. The plasma renin activity and prolactin decreased as a result of L-dopa administration. The administration of a peripheral DA2 dopamine receptor blocker, domperidone (20 mg, orally) prevented the L-dopa-induced reduction in plasma prolactin but failed to block the fall in blood pressure and plasma renin activity. These results suggest that the blood pressure-lowering effect of L-dopa may be mediated through multiple sites involving D1 dopamine receptors, the central nervous system, and the renin-angiotensin system.

UR - http://www.scopus.com/inward/record.url?scp=0026001671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026001671&partnerID=8YFLogxK

M3 - Article

C2 - 1928809

AN - SCOPUS:0026001671

VL - 42

SP - 691

EP - 695

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 9

ER -